Tejara Capital Ltd Invests $2.29 Million in Establishment Labs Holdings Inc. $ESTA

Key Points

• Tejara Capital Ltd has acquired a new stake worth approximately $2.29 million in Establishment Labs Holdings Inc., buying 56,210 shares in the first quarter.
• Analysts have generally rated Establishment Labs positively, with an average target price of $55.80 and a consensus rating of "Moderate Buy."
• Establishment Labs reported a revenue increase of 16.1% year-over-year despite missing EPS estimates with a reported loss of ($0.57) per share.

Tejara Capital Ltd bought a new position in Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The fund bought 56,210 shares of the company's stock, valued at approximately $2,294,000. Tejara Capital Ltd owned about 0.19% of Establishment Labs as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the business. Quarry LP bought a new position in Establishment Labs during the 4th quarter worth about $27,000. ANTIPODES PARTNERS Ltd acquired a new position in shares of Establishment Labs in the 1st quarter valued at about $81,000. Elevation Point Wealth Partners LLC acquired a new position in shares of Establishment Labs in the 1st quarter valued at $207,000. Patriot Financial Group Insurance Agency LLC acquired a new position in Establishment Labs in the 1st quarter worth about $234,000. Finally, Hood River Capital Management LLC raised its position in Establishment Labs by 236.4% during the fourth quarter. Hood River Capital Management LLC now owns 5,920 shares of the company's stock worth $273,000 after acquiring an additional 4,160 shares during the period. Institutional investors own 72.91% of the company's stock.

Analyst Ratings Changes

Several research firms recently commented on ESTA. Canaccord Genuity Group started coverage on Establishment Labs in a research note on Wednesday. They issued a "buy" rating and a $60.00 price objective for the company. Wall Street Zen downgraded Establishment Labs from a "hold" rating to a "sell" rating in a research report on Saturday. Mizuho lifted their target price on shares of Establishment Labs from $58.00 to $70.00 and gave the company an "outperform" rating in a report on Wednesday, July 16th. BTIG Research assumed coverage on Establishment Labs in a research report on Friday, May 16th. They issued a "buy" rating and a $62.00 target price for the company. Finally, Citigroup boosted their target price on Establishment Labs from $38.00 to $47.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 9th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Establishment Labs has an average rating of "Moderate Buy" and a consensus target price of $56.50.

Establishment Labs Price Performance

ESTA stock traded up $1.39 during trading on Wednesday, reaching $39.09. 510,102 shares of the company were exchanged, compared to its average volume of 476,413. Establishment Labs Holdings Inc. has a 52-week low of $26.56 and a 52-week high of $50.85. The company has a debt-to-equity ratio of 9.71, a quick ratio of 1.67 and a current ratio of 2.84. The stock's 50 day moving average price is $40.76 and its 200 day moving average price is $37.17. The company has a market cap of $1.13 billion, a P/E ratio of -12.82 and a beta of 0.83.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.03). Establishment Labs had a negative net margin of 49.89% and a negative return on equity of 224.34%. The business had revenue of $51.30 million during the quarter, compared to analysts' expectations of $50.80 million. During the same period last year, the company earned ($0.62) EPS. The firm's revenue for the quarter was up 16.1% on a year-over-year basis. Establishment Labs has set its FY 2025 guidance at EPS. As a group, analysts predict that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current fiscal year.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.